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Mesenchymal Stem Cell-
Conditioned Medium Reduces 
Disease Severity and Immune 
Responses in Inflammatory 
Arthritis
Alasdair G. Kay1,3, Grace Long2, George Tyler2, Andrei Stefan3, Stephen J. Broadfoot4,  
Anna M. Piccinini5, Jim Middleton6 & Oksana Kehoe3
We evaluated the therapeutic potential of mesenchymal stem cell-conditioned medium (CM-MSC) as an 
alternative to cell therapy in an antigen-induced model of arthritis (AIA). Disease severity and cartilage 
loss were evaluated by histopathological analysis of arthritic knee joints and immunostaining of 
aggrecan neoepitopes. Cell proliferation was assessed for activated and naïve CD4+ T cells from healthy 
mice following culture with CM-MSC or co-culture with MSCs. T cell polarization was analysed in CD4+ T 
cells isolated from spleens and lymph nodes of arthritic mice treated with CM-MSC or MSCs. CM-MSC 
treatment significantly reduced knee-joint swelling, histopathological signs of AIA, cartilage loss and 
suppressed TNFα induction. Proliferation of CD4+ cells from spleens of healthy mice was not affected 
by CM-MSC but reduced when cells were co-cultured with MSCs. In the presence of CM-MSC or MSCs, 
increases in IL-10 concentration were observed in culture medium. Finally, CD4+ T cells from arthritic 
mice treated with CM-MSC showed increases in FOXP3 and IL-4 expression and positively affected the 
Treg:Th17 balance in the tissue. CM-MSC treatment reduces cartilage damage and suppresses immune 
responses by reducing aggrecan cleavage, enhancing Treg function and adjusting the Treg:Th17 ratio. 
CM-MSC may provide an effective cell-free therapy for inflammatory arthritis.
There is no cure for Rheumatoid Arthritis (RA) and life expectancy of sufferers may be reduced by up to 18 years1. 
Therapeutic interventions include disease modifying anti-rheumatic drugs (DMARDs) and biologic treatments 
such as anti-TNFα, anti-IL1, anti-IL6R, anti-CD20 and T-cell co-stimulation blockers. However, 30–58% of 
patients do not respond to biologics such as anti-TNFα2–4, 30–40% lose responsiveness over time5,6 and ~50–58% 
discontinue the therapy within 2 years3,4,7. Furthermore, biologic therapies can cause severe side effects including 
increased risk of infection, hypertension and lymphoma1, are expensive and require continuous subcutaneous 
injections7. There is therefore a need for efficacious, safer and affordable therapeutics.
Alternative treatments include stem-cell therapy. Mesenchymal stem cells (MSCs) exert immunomodulatory 
functions, including inhibition of T cell proliferation, interference with B cell function and dendritic cell matura-
tion and promotion of anti-inflammatory macrophage-mediated responses8. Although stem-cell therapy presents 
a promising alternative treatment, questions remain over differentiation of stem cells where tissue regeneration 
is not the primary goal. Moreover, autologously sourced MSCs must be harvested from patients and cultured in 
vitro to achieve therapeutic cell numbers.
We previously demonstrated that MSCs reduce inflammation in a murine antigen-induced arthritis (AIA) 
model9. MSCs respond to the inflammatory environment by enhancing expression of immunosuppres-
sive factors thereby influencing target cells through paracrine mechanisms10. This involves the production of 
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signalling molecules such as TGF-β1, IL-10, CCL9, IFN-α, IFN-β, nitric oxide (NO), VEGF, FGF, HGF, PDGF 
and membrane-bound vesicles, including microvesicles and exosomes11. We therefore hypothesised that these 
soluble factors, which are present in serum-free MSC-conditioned medium (CM-MSC)12–19, may be responsible 
for the therapeutic effects of MSCs12–15.
Similarly to MSCs, CM-MSC can be therapeutically administered. Thus, here, we tested the therapeutic poten-
tial of CM-MSC in the AIA model of inflammatory arthritis. The effects of CM-MSC therapy were directly com-
pared to those of MSC therapy through assessment of histological outcomes, TNF-α production and cartilage 
loss. The immunomodulatory action of CM-MSC was investigated through examination of T cell activation, 
differentiation and proliferation, and quantification of immunomodulatory factors. We propose CM-MSC as a 
potential therapeutic approach for the treatment of inflammatory arthritis.
Results
CM-MSC ameliorates severity of inflammatory arthritis. AIA is a well-established acute model of 
inflammatory arthritis that mimics many clinical and histopathological changes seen in human RA20–23.
CM-MSC treatment reduced joint swelling as a measure of inflammation compared to SFM control at days 2 
(p < 0.01), 3 (p < 0.05), 7 (p < 0.05) and 14 (p < 0.05) post-arthritis induction (2 way ANOVA with Bonferroni 
post-hoc) (Fig. 1a, Table S1). Significant reductions were also recorded in synovial infiltrate, hyperplasia of the 
synovial intima and cartilage loss (p < 0.05) at day 3 following CM-MSC treatment and in overall arthritis index 
Figure 1. Effects of intra-articular injections of CM-MSC in AIA. (a) Knee diameter (mm) as an index of swelling 
(joint inflammation) measured at days 1, 2, 3, 7 and 14 after arthritis induction. Significant reductions are seen 
following CM-MSC injection in AIA mice (n = 21 (day 1 & 2), 16 (day 3), 12 (day 7), 6 (day 14) mice per group). 
(b) Histopathological symptoms of AIA used to assess disease severity. Representative images for low and high 
scoring taken from CM-MSC treated joints and control SFM treated joints respectively. Arrows show areas 
of interest. Data indicates CM-MSC prompts reductions in synovial infiltrate (leukocyte accumulation in the 
synovium), hyperplasia of the synovial intima and cartilage depletion (p < 0.05) at day 3 post-arthritis induction. 
Arthritic Index is reduced in CM-MSC treated mice at days 3 and 7 post-arthritis induction (p < 0.001 and 
p < 0.05 respectively) with no difference detected at day 14 (p = 0.41). (c) Cells involved in aggrecan cleavage due 
to ADAMTS5 and MMP activity (%). CM-MSC significantly reduces aggrecan breaks due to ADAMTS5 and 
MMPs. Representative positive DIPEN staining (c1) shows extracellular matrix staining, which is absent in control 
stains (c2) (scale bars = 200 µm) (*p < 0.05; **p < 0.01; ***p < 0.001).
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at 3 days and 7 days post-arthritis induction (p < 0.001, p < 0.05 respectively) (Mann Whitney) (Fig. 1b). By day 
14, knee sections displayed signs of recovery and all histological scores were reduced in control and treated ani-
mals, giving no significant difference between control and test arthritis index at this time. Overall, these results 
indicate that CM-MSC treatment significantly reduces disease severity and acute cartilage damage in AIA.
CM-MSC therapy reduces aggrecan breakdown. To further examine the mechanism underlying 
reduction in cartilage loss, we assessed the presence of the neoepitopes …NVTEGE and …VDIPEN gener-
ated during the enzymatic cleavage of aggrecan 3 days after arthritis induction. Compared to MSC treatment, 
CM-MSC showed a higher trend in the reduction of aggrecan cleavage in both early, ADAMTS-driven, and late, 
MMP-driven degradation (CM-MSC p < 0.05, p < 0.001 respectively, MSC p < 0.05 for both, 2-way ANOVA) 
(Fig. 1C, Table S2) with clearly visible regions of extracellular staining of aggrecan neoepitopes occurring in 
untreated cartilage that are not visible in CM-MSC joints. No differences were found between CM-MSC and MSC 
treatments at any time point (p > 0.05). Together, these data indicate that CM-MSC and MSC treatments have 
similar therapeutic efficacy in AIA.
CM-MSC treatment prevents TNFα rise in serum from arthritic mice. TNFα is a key driving 
cytokine in the pathogenesis of RA. To determine whether amelioration of AIA following CM-MSC treatment 
was associated with TNFα blockade or antagonism, we measured changes in TNFα levels in serum of arthritic 
mice. As expected, SFM control mice showed increasing TNFα levels in serum from day 3 to 14 and 7 to 14 
post-arthritis induction (Fig. 2, Table S3) (p < 0.001, p < 0.05 respectively, 2 way ANOVA, n = 6). CM-MSC treat-
ment prevented these TNFα increases observed over time although there were no statistically significant differ-
ences found between levels of TNFα in serum of CM-MSC treated or SFM treated animals.
CM-MSC has no effect on T cell proliferation. We next investigated whether the therapeutic effect 
observed upon treatment with CM-MSC or MSCs was due to changes to T cell function, which plays a central role 
in RA. T cell proliferation was assessed for percentage of non-dividing cells, peaks of gradual division (proliferative 
index)24 representative of the proportion of cells undergoing division accounting for population undergoing varied 
total cycles of division (e.g. accounting for cells that undergo less/more than the average number of population dou-
blings), and 24 hour proliferative cycles (population doublings)25 for T cells isolated from spleens of healthy mice 
following in vitro activation. T cells do not proliferate in culture, unless activated with anti-CD3/CD28, and undergo 
cell death in absence of IL-2, which is produced in vivo by activated T cells26. Proliferative cycles were assessed using 
Violet Proliferation Dye (VPD450) observing peaks for each proliferative cycle completed (Fig. 3a).
To investigate inhibition of T cell activation in co-culture with MSCs, we measured IL-10 in CM-MSC and 
cell supernatant collected after 5 day of co-culture. When comparisons were made with serum-free RPMI 1640 
used in controls, a significant increase in IL-10 was observed in medium of T cells following co-culture with 
MSC (p < 0.05) and CM-MSC (p < 0.01) (Fig. 3b, Table S5) (1 Way ANOVA with Dunn’s post-hoc). We did not 
detect IL-10 in CM-MSC prior to application to the cells. These data indicate that, similarly to MSCs, CM-MSC 
increases IL-10 production in co-culture with activated T cells.
The presence of MSCs in co-culture reduced the number of proliferative cycles (p < 0.001, 1-way ANOVA 
with Tukey’s post-hoc, n = 11) (Fig. 3c) and proliferative index in comparison to T cells alone and T cells 
with CM-MSC (p < 0.001, 1-way ANOVA with Tukey’s post-hoc) (Fig. 3d). No difference was found between 
CM-MSC and T cells alone (Table S4).
CM-MSC enhances FOXP3 expression in spleens and lymph nodes. Increased production of IL-10 
during T cell co-culture with MSC or CM-MSC led us to investigate the polarisation of naïve T cells into effector 
lineages with immunosuppressive/anti-inflammatory function following CM-MSC or MSC treatment. FOXP3 
Figure 2. CM-MSC suppresses TNF-α in serum. ELISA of circulating TNF-α in blood serum measured at 
3, 7 and 14 days post arthritis induction. CM-MSC suppresses time-dependant increases in TNF-α observed 
in control animals (n = 6 mice per group) but does not statistically differ from control for each timepoint. 
(*p < 0.05; ***p < 0.001).
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is a key transcriptional regulator for Treg development and function, with increased expression conferring 
enhanced immunosuppressive properties27. Tregs isolated from spleens and lymph nodes in close proximity to 
the treated joint were analysed for CD4+ CD25+ FOXP3+ positivity. In the spleen, 3 days post arthritis induc-
tion, the mean percentage of CD4+ cells did not vary between MSC, CM-MSC and SFM control treatments 
(9.83 ± 1.54%, 11.36 ± 1.60%, 10.30 ± 1.60% respectively). However, lymph nodes showed significantly decreased 
numbers of CD4+ cells in both MSC and CM-MSC treatments (12.06 ± 0.99%, p < 0.001 and 13.49 ± 1.39%, 
p < 0.05, respectively) compared to SFM controls (16.11 ± 1.38%)) (ANCOVA with Bonferroni post-hoc) 
[Fig. 4a]. No differences were observed between CM-MSC and MSC treatments.
The cellular expression of FOXP3 increased upon both MSC (Mean fluorescence intensity (MFI) 504.4 ± 18.3, 
p < 0.001) and CM-MSC (MFI 500.6 ± 18.1, p < 0.05) treatments at day 3 compared to controls (MFI 
459.6 ± 18.3) in spleens of AIA mice and upon MSC treatment (MFI 1048.2 ± 88.3, p < 0.05) compared to con-
trols (MFI 813.5 ± 123.1) in lymph nodes (ANCOVA with Bonferroni post-hoc) [Fig. 4b]. CM-MSC showed a 
higher tendency to increase Treg numbers in the spleen compared to MSC treatment (normalised per mg tissue; 
MSC: 4249 ± 2930; CM-MSC: 5273 ± 3852; control: 3832 ± 2872; p > 0.05, 1 Way ANOVA, n = 6). These data 
show that CM-MSC treatment of arthritic mice enhances FOXP3 expression in CD4+ T cells.
Increased production of IL-4 and FOXP3 and restored Treg:Th17 balance following CM-MSC 
treatment. The pathogenesis of RA is characterized by an imbalance between anti-inflammatory (Th2, Treg) 
and pro-inflammatory (Th1, Th17) T cells with decreased Treg and increased Th17 cell numbers28. To further 
investigate T cell differentiation, intracellular staining was performed to establish the expression of IL-4 (Th2) and 
IFN-γ (Th1) and the ratio of FOXP3 (Treg) to IL-17a (Th17) expressing cells in splenocytes from arthritic mice 
following MSC or CM-MSC treatment.
Figure 3. Decreased T cell proliferation in co-culture with MSC assessed using Violet Proliferation Dye 450 
(VPD450) (a) Proliferative cycle representative images show individual colourless peaks with a green peak 
representing initial T cell population at day 1 and red peaks demonstrate unstained T cell signal intensities as 
negative control. MSC/T cell co-culture with activation reduces peak frequency and height. (b) ELISA of IL-10 
in conditioned medium from T cell culture shows increased concentration of IL-10 compared to fresh serum-
free RPMI medium control (n = 4). (c) Proliferative cycles per 24 hours culture (population doubling frequency) 
and (d) proliferative capacity (representative of proportion of cells undergoing proliferation) are significantly 
reduced following MSC co-culture (n = 4 spleens with 2 replicates for each) (*p < 0.05, ***p < 0.001).
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IL-4 expression increased significantly following CM-MSC treatment (Fig. 4c), indicating that CM-MSC 
enhances Th2 cell immunosuppressive activity. Although IL-4 expression was not significantly increased follow-
ing MSC treatment, the proportion of IL-4 expressing cells (Th2) (27.33 ± 4.64%) significantly increased com-
pared to CM-MSC (20.77 ± 3.42%) and control (20.97 ± 2.53%) (p < 0.05, 1-way ANOVA with Tukey’s post-hoc, 
n = 12). T cell expression of IFN-γ was not affected by CM-MSC or MSC.
CM-MSC treatment also decreased the proportion of pro-inflammatory Th17 cells (20.99 ± 4.93%) com-
pared to MSC treatment (30.55 ± 6.37%) (p < 0.05, 1-way ANOVA with Tukey’s post-hoc, n = 12) and 
control (23.39 ± 5.18%). Furthermore, the ratio of FOXP3:IL17a expressing cells significantly increased fol-
lowing CM-MSC treatment (2.52 ± 1.80) compared to SFM control (1.18 ± 0.75; p < 0.01) and MSC treatment 
(1.74 ± 1.32; p < 0.05; Kruskall-Wallis with Dunn’s post-hoc, n = 12) (Fig. 4d). Thus, CM-MSC promotes immu-
nosuppressive/anti-inflammatory T cell activity and restores the Treg/Th17 balance in AIA.
Discussion
We previously demonstrated that MSC therapy in AIA reduces inflammation, leukocyte (predominantly neutro-
phil) exudate into the joint cavity and disease severity9. However, MSC therapy requires surgery to harvest autol-
ogous cells and differentiation of transplanted cells is difficult to control. Such limitations restrict translation of 
stem cell therapies into clinical use. Stem cell-based, cell-free therapies bypass these issues and allow banking and 
standardisation of treatments, facilitating rapid clinical translation. Here, we evaluated the therapeutic potential 
of cell-free CM-MSC as a novel strategy for the treatment of inflammatory arthritis and test the hypothesis that 
Figure 4. Increased immunosuppressive/anti-inflammatory T cell subsets following CM-MSC treatment at 
3 days post induction of arthritis. (a) Surface staining of CD4 assessed proportion of CD4+ cells in spleens 
(left) and lymph nodes (right). (b) Intracellular staining for key cytokines characteristic of Treg (FOXP3) in 
spleens (left) and lymph nodes (right) and (c) Th2 (IL4) following 4 hours culture with inhibition of protein 
transport using Brefeldin A for T cells from CM-MSC and MSC treated mice and SFM treated controls (mean 
fluorescence intensity (MFI)). (d) The ratio of percentage FOXP3+ to IL17a+ cells (Treg:Th17) was calculated 
showing an improved ratio of FOXP3:IL17a expression following CM-MSC co-culture. All data were obtained 
from AIA mice at day 3 post arthritis induction. (*p < 0.05; **p < 0.01; ***p < 0.001).
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therapeutic MSCs act in a paracrine manner. Our ex-vivo and in-vivo studies provide evidence for CM-MSC act-
ing as a therapeutic agent by significantly reducing the histopathological signs of inflammation and joint damage 
characteristic of arthritis, including cartilage breakdown. We demonstrate that CM-MSC exerts its immunosup-
pressive/anti-inflammatory function by increasing FOXP3 expression in Tregs and improving Treg:Th17 ratios. 
CM-MSC treatment not only closely recapitulates the effects seen upon MSC treatment9, but also eliminates the 
risks linked to cell transplants.
CM-MSC treatment reduced cartilage destruction in AIA mice. We investigated aggrecan neoepitopes for-
mation through enzymatic cleavage by ADAMTS and MMPs. RA is a disease characterised by progressive joint 
destruction. The enzymatic cleavage of aggrecan is a key event in the development of RA29 and is due to the action 
of proteolytic enzymes directed by inflammatory mediators such as cytokines, prostaglandins, matrix degrada-
tion products, complement and growth factors30. Moreover, RA is characterised by the formation of a pannus, 
accumulated rheumatoid synovial tissue that invades cartilage and bone. However, cartilage breakdown occurs in 
RA even in the absence of pannus formation31. Matrix metalloproteinases (MMPs), predominantly MMP’s −1, 
−3 and −1332, and aggrecanases, in particular aggrecanase 1 (ADAMTS4) and aggrecanase 2 (ADAMTS5)33–35, 
are responsible for the breakdown of cartilage and release of peptide fragments, termed neoepitopes, into the 
rheumatoid joint. RA sufferers have been shown to have reduced intact aggrecan, but increased aggrecan frag-
ments in circulation36. Citrullinated epitopes of degraded proteoglycans from cartilage have been detected in 
>60% of RA sufferers and implicated in increased pro-inflammatory cytokine production in clinical patients37–40. 
Furthermore, stimulation of peripheral blood mononuclear cells of RA patients with citrullinated aggrecan 
neoepitopes leads to a pro-inflammatory response characterised by T cell proliferation and increased formation 
of IL17a expressing Th17 cells not observed with PBMC of healthy individuals39. The inflammatory response 
to citrullinated self-antigens has been shown to increase over responses to wild type antigens in mice41 and to 
native epitopes in humans42. Anti-citrullinated protein antibodies occur with higher specificity (~96%) in RA 
patient serum over rheumatoid factor43. Autoimmunity may, in fact, develop in RA largely due to extracellular 
fragments such as aggrecan neoepitopes forming MHCII complexes with cells that fail to be negatively selected 
during thymic development. For example, aggrecan specific B cells have been shown to readily acquire aggrecan 
neoepitopes and function in antigen presenting to CD4+ T cells leading to T cell activation and effector T cell 
formation44. Consequently, autoantigen release, in the form of aggrecan neoepitopes from inflamed cartilage 
where joint destruction is present, may promote RA pathology even in the absence of pannus formation. MMP 
activation occurs in response to cytokine signalling, in particular pro-inflammatory cytokines IL-1β and TNF-α, 
which are key therapeutic targets in the control of RA using biologic treatments. An awareness of effects of treat-
ment methodologies on the breakdown of aggrecan is vital in the development of effective novel therapeutics.
We assessed …NVTEGE (ADAMTS-cleaved) and …VIPEN (MMP-cleaved) aggrecan neoepitope formation 
in mouse knee-sections following CM-MSC treatment. Early cartilage destruction in AIA is mediated by the 
ADAMTS family of enzymes15,19 and loss of the ADAMTS5 gene has been shown to prevent cartilage destruction 
in mouse models of arthritis11. CM-MSC treatment reduced aggrecan degradation by both ADAMTS and MMPs. 
CM-MSC therapy provided a more beneficial effect than MSC treatment in the time period examined, poten-
tially due to the need for MSCs to home and adjust to their environment. Our results in mice support previous 
studies examining neoepitope formation due to MMP and aggrecanase activity in humans, with no co-ordinated 
activity of the enzymes and regional correlation between cartilage damage and epitope formation, mainly in the 
superficial layer of cartilage45. Our results demonstrate potentially beneficial reductions in neoepitope formation 
following CM-MSC treatment which may therefore exacerbate the progression of RA through a resolution of 
citrullinated aggrecan neoepitope formation.
Following CM-MSC treatment, we did not observe a reduction in circulating TNF-α as seen upon MSC treat-
ment but over time increases in circulating TNF-α were observed in untreated AIA mice. CM-MSC suppressed 
the increase in TNF-α observed in untreated AIA mice. We hypothesised that soluble factors released by MSCs 
reduce endothelial permeability, decreasing leukocyte accumulation in the synovial fluid of inflamed joints9.
Our results showed suppressed proliferation of T cells when co-cultured with MSC but not in the presence of 
CM-MSC alone. There is conflicting reports as to the efficacy of applying soluble molecules secreted by MSC as 
immunomodulatory therapy and some debate as to the mechanism that elicits suppression of T cell proliferation. 
In general, reports confirm the involvement of soluble hepatocyte growth factor (HGF) which induces IL-10 pro-
duction by monocytes46, indoleamine 2,3-dioxygenase (IDO), transforming growth factor (TGF-β1) and prosta-
glandin E2 (PGE2)46–51. A majority of reports of successful suppression of T cell proliferation using soluble factors 
secreted by MSC utilise either transwell systems52–56 or similar methods to inhibit cell contact whilst maintaining 
MSC presence in the system e.g. encapsulated cells57. Additionally, these studies predominantly measure the 
proliferation of T cells in either mixed lymphocyte cultures52–54,56 or in mixed splenocytes55. The interaction of 
MSCs with CD8+ effector T cells, B cells, Natural Killer cells and dendritic cells are well described58–60 and con-
sequently the mechanisms at work in mixed lymphocyte cultures may be mediated through MSC influences on 
CD4− cells that subsequently act upon CD4+ T cells. Studies reporting the need for cell contact to exhibit a pro-
liferative effect commonly utilise cell supernatants61 or removal of MSCs from co-culture prior to measurement, 
and application of enriched T cells rather than mixed lymphocyte populations62–64. These variations in study 
methodology make it difficult to ascertain the precise mechanisms involved in suppression of T cell proliferation 
though it seems likely that, whilst CM-MSC conveys reduced potency in comparison to the influence of MSC in 
the system, the inclusion of mixed population lymphocytes may restore similar immunomodulatory properties 
of CM-MSC52–56.
In this study, T cells were cultured with CM-MSC and activated with a CD3ɛ/CD28 activation beads 
(Miltenyi) at the time of seeding T cells into MSC plated wells. T cells activated with cognate antigen commence 
proliferation after approximately 24 hours62, so results utilising single-dose treatment with CM-MSC could poten-
tially reflect a depletion of the required suppressive stimuli prior to the initiation of T cell division. In the AIA 
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murine model of inflammatory arthritis, T cell proliferation is initiated with antigen challenge and treatments 
are administered 24 hours post-induction. Consequently, in vivo T cell proliferation would be underway in this 
model at the time of MSC or CM-MSC intervention. The anti-proliferative capacity of secreted factors from MSC 
may therefore be applied here in a timely manner to elicit a positive therapeutic response, not ruling out the pos-
sibility that treatment with CM-MSC is inducing suppression of T cell proliferation in vivo even when suppressive 
effects are not observed for CM-MSC in vitro.
Our findings are consistent with previous studies that suggest cell supernatants require increased concentra-
tions compared to MSC numbers used in co-culture63–65. Similarly, our findings confirmed that the presence of 
MSC maintains T cell survival in the absence of CD3ɛ/CD28 activation consistent with prior studies63. MSCs of 
bone marrow origin exert suppressive effects through arrest of lymphocyte cell cycle66,67, apoptosis of T cells67,68 
or induction of T cell suppressive dendritic cells that induce Treg production and enhance IL-10 secretion69,70. 
Interactions are, however, dependent on MSC dose concentration66. Some evidence suggests that suppression 
seen with higher concentration CM-MSC may act via cell apoptosis whilst transwell studies commonly describe 
T cell cycle arrest67,68. With direct cell contact, low dose MSC are sufficient to suppress T cell proliferation whilst 
CM-MSC alone requires increased equivalent MSC:T cell concentrations to exhibit suppressive effects64,65,67,68. 
In this study, proportionally equivalent dosage of CM-MSC (to match MSC secretions for 5.0 × 105 cells over 
a 48 hour period) was assessed for T cell suppression to match MSC concentration for in vivo experimenta-
tion. CM-MSC was not sufficiently potent to induce T cell suppression. This result coupled with the positive 
histological improvements suggest that suppression of T cell proliferation may not be the key mechanism for 
improved outcomes following treatment in AIA, however the timing of treatment administration cannot defini-
tively exclude this possibility. A further study examining dose repeats and timing of application in co-culture for 
CM-MSC and CD4+ T cells may further elucidate the mechanisms involved.
As well as inhibiting proliferation of T cells, MSCs increase Treg numbers and IL-4 and IL-10 expression 
whilst reducing IL-6 and IL-17 secretion and Th1 and Th17 differentiation71–75. Our data show a similar decrease 
in CD4+ T cell numbers in spleen and lymph nodes of arthritic mice upon CM-MSC and MSC treatment, sug-
gesting that CM-MSC is able to convey a response in vivo similar to that of MSC. Our study also shows increased 
Treg numbers upon CM-MSC and MSC treatment and demonstrates that CM-MSC can increase IL-4-expressing 
Th2 cells and FOXP3 expression by activated T cells. The concentration of IL-10 increased in medium of T cells 
co-cultured with MSC or in CM-MSC. The origin of this IL-10 was not assessed and so may be due to produc-
tion by MSCs or T cells. The increased presence of FOXP3 expressing Tregs would likely be associated with an 
increased presence of IL-10 in medium. Furthermore, the soluble secretions of MSC in the presence of activated 
T cells show enhanced IL-10 secretion compared to MSC in standard culture63. These results are in line with 
work done by others showing that mesenchymal cell-derived factors skew T cell polarization toward Treg and 
reduce pro-inflammatory cytokine expression76. Previous reports suggest immunosuppressive effects of MSC 
function through the enhanced activity and development of FOXP3 expressing T cells and not a reduction in 
pro-inflammatory IFN-γ expressing Th1 cells63.
This study is an early demonstration of CM-MSC induced increases in Treg induction and expression of 
FOXP3, alongside positive adjustment of the Treg:Th17 balance, without Th17 or Th2 cell induction at 3 days 
post-arthritis induction in AIA mice. In RA, Treg differentiation is inhibited causing the ratio of Tregs to Th17 
cells to be disrupted77. Our study suggests a therapeutic mechanism for CM-MSC that counteracts this effect.
MSCs stimulated by IL17a function to suppress T cell proliferation (as observed in our co-culture experi-
ments), IFN-γ, TNF-α and IL-2 from Th1 cells and induce Tregs15. IL-17a overexpression accelerates the develop-
ment and severity of synovial inflammation and bone erosion in inflammatory arthritis78. We have shown a shift 
to restore the homeostatic balance of Th17 to Treg cells. Further investigation will include an in vivo examination 
of T cell differentiation using immunohistochemical staining of knee sections to investigate the expression of 
FOXP3 and IL17a in tissue in the mouse joint. We hypothesise that these results will provide evidence that the in 
vitro findings translate to a similar restorative shift in T cell development within the mouse following treatment 
with MSC or CM-MSC. In addition to this, we aim to evaluate the function outcomes of the T cell immuno-
modulation observed by culturing naïve CD4+ T cells isolated from spleens of AIA mice following treatment 
to evaluate their interactions with effector cells. We hypothesise here that the response to cells from CM-MSC 
treated mice will result in reduced activation and proliferation of immune effector cells comparative to control, 
untreated animals. This can be evaluated both in vitro using cells isolated from spleens of AIA mice undergoing 
treatment and in vivo using the current assay technique with immune cell status being assessed using immuno-
histochemistry on joint sections.
We previously showed that MSC therapy reduces the concentration of circulating TNFα which would facil-
itate the restoration of homeostatic T cell differentiation9. We evaluated the differentiation of naïve CD4+ T 
cells to quantify Th1 and Th2 cells and the ratio of Tregs:Th17. CM-MSC, but not MSCs, restored the ratio of 
Tregs:Th17 cells from a diseased state (ratio ~1:1 in SFM controls) to a homeostatic level (ratio ~3:1 in CM-MSC 
treated animals). The reduced polarisation of IL-17a secreting Th17 cells demonstrated here supports our previ-
ous study demonstrating reduced neutrophil accumulation in the joints of MSC treated mice9.
Further work is needed to clarify the prolonged effects of CM-MSC treatment, dose requirements and fre-
quency of treatment to achieve optimal therapeutic outcomes. The potential exists to further refine CM-MSC 
by removing, for instance, waste products of cell metabolism. Genomic and proteomic analysis of CM-MSC 
will identify the anti-inflammatory component(s) of CM-MSC that could be purified and used in isolation or 
in combination to maximise the therapeutic response. Although one of the challenges ahead is to identify the 
exact mechanism of action of CM-MSC in vivo, CM-MSC represents an attractive therapeutic with potential for 
inflammatory arthritis treatment.
This study demonstrates the potential of CM-MSC as a therapy for inflammatory arthritis. Increased expres-
sion of anti-inflammatory, and suppression of pro-inflammatory, cytokines and a reduction in aggrecan breaks 
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can be seen to ameliorate the symptoms of inflammatory arthritis in the AIA model. The exclusion of living cells 
from a cell-based therapy offers several advantages in clinical translation. Treatments can be assessed, measured 
and standardised to ensure reliability and reproducibility. Regulatory restrictions call for tight controls on the 
introduction of living cells from donor to recipient, and these regulations will be more readily met by a “cell-free” 
therapy. The potential for CM-MSC to provide a broad therapeutic strategy for autoimmune inflammatory con-
ditions is significant.
Methods
Antigen-induced arthritis (AIA). Animal procedures were undertaken in accordance with Home Office 
project licence PPL40/3594. AIA was induced in male C57Bl/6 mice (7–8 weeks) as previously described79. 
Swelling was assessed by measuring the difference in diameter between the arthritic (right) and non-arthritic 
(left) knee joints (in mm) using a digital micrometer (Kroeplin GmbH).
Cells. Murine MSCs isolated from BALB/C mice and cryopreserved at early passage (P3-P5)9 were thawed and 
cultured in Iscove Modified Dulbecco Medium (IMDM) (Gibco, UK) supplemented with 9% foetal bovine serum 
(Gibco, UK), 9% horse serum (Gibco, UK) and 1% penicillin-streptomycin (Cell Expansion Medium, CEM). 
Cells (P3-P5) were previously characterised as MSC through immunophenotyping of surface markers with flow 
cytometry and tri-lineage differentiation9.
Production of CM-MSC. MSCs from the same batch used for cell treatment (P3-P5) were seeded in T75 
flasks with CEM (~1.3 × 104 cells/cm2). At 80–90% confluence, cells were washed with PBS and then serum-free 
IMDM media (SF-IMDM). Flasks were incubated for 48 hours with 12 ml SF-IMDM at 37 °C, 5% CO2. SF-IMDM 
with no cells was used as a control (SFM). After 48 hours, medium was removed and centrifuged for 5 minutes at 
1200 × g to remove cell debris. 11 ml of supernatant was transferred to an Amicon Ultra 15 filter (3 kDa cut-off 
membrane) and centrifuged at 4000 × g for 40 minutes at 4 °C. Filters were flushed repeatedly with supernatant 
and concentrated CM-MSC was stored at −80 °C80. Average cell count following removal of CM-MSC for con-
centration was 2.8 × 106 cells.
Intra-articular injection of MSC and CM-MSC. Treatments were 15 μl concentrated CM-MSC or 
5.0 × 105 MSC (P4-P5) resuspended in 15 μl of SF-IMDM. 15 μl of concentrated CM-MSC corresponded to cell 
secretions from 5.08 × 105 cells on average. Treatments or SFM control were injected intra-articularly 1 day post 
arthritis induction with 0.5 ml monoject (29 G) insulin syringes (BD Micro-Fine, Franklyn Lakes, USA) through 
the patellar ligament into the right knee joint. Joint diameters were measured at 2, 3, 7 and 14 days post injection. 
Blood, joints, spleen, inguinal and popliteal lymph nodes were collected immediately post-mortem. Three inde-
pendent experiments were performed. All measures were taken to reduce animal numbers (n = 5–11 per time 
point).
Arthritis Index. Animals were sacrificed for histological analysis at days 3, 7 and 14. Joints were fixed in 
10% neutral buffered formal saline and decalcified in formic acid for 4 days at 4 °C before paraffin embedding. 
Sections (5μm) were stained with haematoxylin and eosin (H&E) or toluidine blue and mounted in Hydromount 
(National Diagnostics) as described previously9. H&E sections were scored for hyperplasia of the synovial intima 
(0 = normal to 3 = severe), cellular exudate (0 = normal to 3 = severe) and synovial infiltrate (0 = normal to 
5 = severe); and Toluidine Blue stained sections for cartilage loss (0 = normal to 3 = severe) by two independent 
observers blinded to experimental groups81. Scores were summated, producing a mean arthritis index.
Immunostaining for aggrecan neoepitopes. Primary antibodies for murine NITEGE and DIPEN were 
donated by John Mort (Shriners Hospital for Children, Montreal). Immunohistochemical staining for aggre-
can breaks was performed using VECTASTAIN Elite ABC Kit (Mouse IgG) (Vectorlabs) following manufactur-
er’s instructions, with biotinylated goat anti-rabbit IgG secondary antibody and DAB (3,3′-diaminobenzidine; 
Sigma-Aldrich). Rehydrated sections underwent antigen retrieval in 1 mM EDTA at 65 °C overnight. Sections 
were blocked using 2.5% goat serum for 20 minutes prior to 30 minutes exposure to primary antibodies, rinsed 
with PBS and then exposed to biotinylated secondary antibody, ABC reagent and DAB before counterstaining 
with Mayer’s Haematoxylin, clearing and mounting. Mean counts were calculated for cells showing adjacent 
matrix stain for NITEGE or DIPEN in femoral and tibial cartilage (n = 11 (day 3), 9 (day 7), 4 (day 14) mice per 
group).
Cytokine Quantification. IL-10 and TNFα in serum and CM-MSC were quantified using mouse 
Quantikine ELISA IL-10 immunoassay (R&D Systems) and TNFα ELISA high sensitivity (eBioscience) respec-
tively, following manufacturer’s instructions.
Detection of Tregs. Spleens from treatment and control animals sacrificed at 2 (n = 4) and 3 (n = 6) days 
post-arthritis induction were weighed and dissociated in PBS using a 7 ml borosilicate glass dounce tissue 
grinder with loose pestle (Fisherbrand). Cells were passed through a 30μm pre-separation MACS SmartStrainer 
(Miltenyi), centrifuged and resuspended in PBS pH 7.2 containing 0.5% bovine serum albumin and 2 mM EDTA. 
Tregs were isolated using CD4+ CD25+ Regulatory T Cell Isolation Kit (Miltenyi) following manufacturer’s 
instructions. CD4+ CD25+ cells were stained with CD4-FITC, CD25-APC and FOXP3-PE and analysed on a 
BD FACS CANTO II (BD Biosciences).
Co-culture of T cells with MSC/CM-MSC. Proliferation of activated T cells was assessed as a measure 
of T cell deactivation. Initially, 5 × 104 MSCs were cultured in 96-well plates for 24 hours at 37 °C. CD4+ T cells 
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were purified from spleens and lymph nodes (popliteal/inguinal) of healthy C57Bl/6 mice using the CD4+ T Cell 
Isolation Kit (Miltenyi) following manufacturer’s instructions. T cells were seeded at a density of 5.0 × 105/well 
in 250 μl RPMI medium with 10% FBS and MSCs (ratio 10:1) or with CM-MSC for 5 days. T cells alone served 
as control. Cells were activated using anti-Biotin MACSiBead Particles (Miltenyi) (ratio 2:1). Proliferation was 
assessed through reduction in signal intensity using VPD450 Violet proliferation dye (BD Biosciences) following 
previously described methodologies to calculate proliferative index and proliferative cycles24,25.
Intracellular staining. Spleens and lymph nodes (popliteal/ inguinal) were collected from mice 3 days 
post-arthritis induction and dissociated as described. Splenocytes and lymph node cells were seeded separately at 
1.0 × 106 cells/well in 96-well plates (Sarstedt) in RPMI-1640 with 10% FBS, 0.05 μg/mL IL-2 and 10 μg/ml brefel-
din A (Sigma) and activated with cell stimulation cocktail (eBioscience) at 37 °C for 4 hours. No cell stimulation 
cocktail and no brefeldin A served as controls. Following activation, cells were resuspended in 2 mM EDTA in 
PBS and Tregs (CD4+ CD25+ FOXP3+) were isolated using the CD4+ CD25+ Regulatory T Cell Isolation Kit 
(Miltenyi) following manufacturer’s instructions; or stained for T cell subset identification. For this, cells were 
permeabilised using permeabilisation buffer kit (eBioscience) and intracellularly stained with anti-mouse IFNγ 
(Th1), IL-4 (Th2) or IL17a (Th17) (eBioscience). Cells were analysed on a BD FACS Canto II flow cytometer and 
comparisons drawn for percentage CD4+ cells and signal intensity (XGeoMean) for each antibody.
Statistical analysis. Data were tested for equal variance and normality using D’Agostino & Pearson omni-
bus normality test. Differences between groups were compared using 1-way ANOVA for parametric data or 
Kruskall-Wallis ANOVA for non-parametric, or 2 Way ANOVA with Bonferroni correction, as stated. All sta-
tistical analysis was carried out using Prism 5 (GraphPad software) or IBM SPSS Statistics 24.0, with P < 0.05 
deemed statistically significant. Results are expressed as mean ± confidence interval. For regulatory T cell anal-
ysis, a reduction in cell size was observed following permeabilisation. Covariate of cell size (forward scatter, 
FSC-A) was used to compensate (ANCOVA).
Data availability. All data generated or analysed during this study are included in this published article (and 
its Supplementary Information files).
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